What’s Inside Johnson & Johnson (JNJ)’s Pharmaceuticals Business? – Medivation Inc (MDVN), Merck & Co., Inc. (MRK)

When it comes to health care companies, there’s no bigger name than the largest firm in the business: Johnson & Johnson (NYSE:JNJ).

What doesn’t Johnson & Johnson (NYSE:JNJ) produce? From pharmaceuticals to consumer care goods to medical devices, this major medical player has it all. That can make it tough on investors trying to understand this highly diversified company, however: With so many parts, what do you need to keep an eye on? To get a grip on this colossus of the health care sector, let’s take a look at Johnson & Johnson (NYSE:JNJ) and the company’s top pharmaceuticals powering its revenues today.

Johnson & Johnson (NYSE:JNJ)Rising to the top
Anything related to Johnson & Johnson (NYSE:JNJ)’s pharmaceuticals has to start with Remicade. The anti-inflammatory biologic is the engine to this company’s drug sales, pulling down more than $6 billion in 2012 alone at year-over-year growth of nearly 12%. This drug has crushed expectations and keeps on rising.

Merck & Co., Inc. (NYSE:MRK), Johnson & Johnson (NYSE:JNJ)’s partner on Remicade, turned over the marketing rights to the drug in certain geographic areas back in 2011, fueling Johnson & Johnson (NYSE:JNJ)’s share of the revenue. Remicade doesn’t face a patent expiration until 2018 in the U.S. and 2014 in Europe and Japan; its status as a biologic, rather than a chemical compound, should also impede generic drugmakers from stepping in to launch competition too quickly. Remicade might not be able to keep this level of growth up with such high sales, but it’s a safe bet to keep powering the foundation of Johnson & Johnson (NYSE:JNJ)’s pharmaceutical revenue for the next few years.

Johnson & Johnson (NYSE:JNJ)’s pharmaceuticals are more than just Remicade however, even if the drug takes the spotlight today. Fellow immunology drug Stelara has put on a show worthy of any growth investor’s attention recently as sales swelled nearly 39% in 2012 to exceed the $1 billion mark. This drug, used to treat severe plaque psoriasis, was estimated early last year to hit peak sales of more than $1.5 billion by 2016, but its surge could send sales far over that mark.

Stelara has also shown effectiveness in combating symptoms of Crohn’s disease in clinical trials. While the drug’s still being evaluated as a treatment option, if Stelara is ever approved to fight Crohn’s — an inflammatory bowel disease afflicting more  than 1 million people — J&J could see the drug’s sales soar.

Some of J&J’s former blockbuster heavyweights are on the way down due to generic competition, such as neurology drugs Concerta and Risperdal. However, new blockbuster arrivals have risen to take their place. Oncology drugs Velcade and Zytiga both grew significantly last year — the latter by a whopping 319% to $961 million. Zytiga has picked up expanded approval as a pre-chemo prostate cancer drug from the FDA recently, and peak sales could hit up to $1.8 billion. While Zytiga’s facing tough competition – Medivation Inc. (NASDAQ:MDVN)‘s own prostate cancer drug and rival Xtandi is predicted to reach peak sales of up to $2.2 billion — the drug still should help J&J stay on track.

Leading the sales of today
With Remicade as its foundation, Johnson & Johnson (NYSE:JNJ)’s pharmaceuticals business is in good hands in the near future. Promising growth stories like Stelara and Zytiga offer blockbuster power in coming years, and with a pipeline full of tomorrow’s cash cows, J&J’s drugs are on the right track.

The article What’s Inside Johnson & Johnson’s Pharmaceuticals Business? originally appeared on Fool.com.

Fool contributor Dan Carroll has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The 9 Most Dangerous Countries for Tourists to Visit

Reign of Terror: The 10 Most Ruthless Politicians in History

On the Move: The 10 Fastest Growing Businesses in 2015

Fast Money: The 10 Highest Paying Fast Food Restaurants

Mixing It Up: The 14 Best Music Mashups of 2014

Rito Pls Buff: The 10 Least Played Champions in LoL Season 4

10 Covers of Popular Songs that are Better than the Originals

Must See TV: The 9 Most Anticipated Shows of 2015

The 15 Biggest Box Office Bombs of All Time

10 Things The World Can’t Stand About Americans

Picture Perfect: The 6 Smartphones with the Best Cameras

The 10 Best Countries To Work In the World

A Profitable Day At The Track: 5 Tips For Betting On Horses

Tearing You Apart: 6 Bad Habits That Ruin Relationships

Learning on the Job: The 6 Biggest Mistakes Parents Make

Shopaholics Rejoice: The 12 Biggest Malls in the World

Fright Night: 10 Horror Movies Based on True Stories

Mach Mania: The 10 Fastest Jets in the World

Military Heavyweights: The 10 Countries with the Most Tanks

All In: The 7 Richest Poker Players in the World

Abracadabra: The 10 Best Magicians in the World

The 10 Richest Asian Countries in the World in 2014

Eyes in the Sky: 10 Things You Need to Know About Drones

Rising Stars: The 6 Best Silicon Valley Startups

Military Muscle: The 5 Most Advanced Armies in South America

All that Glitters: The 7 Most Luxurious Jewelry Brands in the World

5 Things You Didn’t Know About ISIS but Should

Empowering Your Money: The 5 Best Energy Stocks to Invest In

The 11 Best Android Apps You Can’t Get on iOS

The 10 Most Important International Conflicts in 2014

Mood Enhancers: The 20 Most Uplifting Songs of all Time

Lover Beware: The 8 Countries that Cheat the Most

Breath of Fresh Air: The 25 Countries with the Best Air Quality on the Planet

Singles Beware: The 8 Worst Mistakes Made on First Dates

Healthy and Happy: The 10 Countries with Lowest Healthcare Costs

The 6 Best Company Team Building Activities to Build Workplace Camaraderie

Ships Ahoy: The 10 Busiest Shipping Ports in the World

10 Productivity Tips to Save You Time and Help You Do More With Less

Grab a Bite: The Most Popular Fast Food Restaurants in America

Friday Night Thirst: The 10 Most Popular Cocktails in the World

The 6 Greatest Unsolved Mysteries We May Never Figure Out

7 Useless Products You Never Should’ve Bought

The 5 Reasons Why You’re Single and Miserable

The 7 Most Addictive Foods in the World We Can’t Stop Eating (Even Though We Should)

5 Amazing Places You Can Swim with Dolphins

The Top 7 Most Livable Countries In The World

The 10 Most Expensive Baseball Cards Ever Pulled From A Pack

The 5 Easiest Second Languages to Learn for English Speakers

Silver Spoon: The 6 Richest Families in the World

The 20 Countries with the Largest Prison Populations in the World

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!